1. Home
  2. BCAB vs ANY Comparison

BCAB vs ANY Comparison

Compare BCAB & ANY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • ANY
  • Stock Information
  • Founded
  • BCAB 2007
  • ANY N/A
  • Country
  • BCAB United States
  • ANY United States
  • Employees
  • BCAB N/A
  • ANY N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • ANY Finance: Consumer Services
  • Sector
  • BCAB Health Care
  • ANY Finance
  • Exchange
  • BCAB Nasdaq
  • ANY Nasdaq
  • Market Cap
  • BCAB 27.0M
  • ANY 25.2M
  • IPO Year
  • BCAB 2020
  • ANY N/A
  • Fundamental
  • Price
  • BCAB $0.31
  • ANY $0.55
  • Analyst Decision
  • BCAB Buy
  • ANY Strong Buy
  • Analyst Count
  • BCAB 2
  • ANY 1
  • Target Price
  • BCAB $5.00
  • ANY $3.00
  • AVG Volume (30 Days)
  • BCAB 1.1M
  • ANY 315.3K
  • Earning Date
  • BCAB 03-25-2025
  • ANY 03-21-2025
  • Dividend Yield
  • BCAB N/A
  • ANY N/A
  • EPS Growth
  • BCAB N/A
  • ANY N/A
  • EPS
  • BCAB N/A
  • ANY N/A
  • Revenue
  • BCAB $11,000,000.00
  • ANY $21,657,000.00
  • Revenue This Year
  • BCAB N/A
  • ANY N/A
  • Revenue Next Year
  • BCAB N/A
  • ANY N/A
  • P/E Ratio
  • BCAB N/A
  • ANY N/A
  • Revenue Growth
  • BCAB N/A
  • ANY 38.44
  • 52 Week Low
  • BCAB $0.24
  • ANY $0.53
  • 52 Week High
  • BCAB $4.02
  • ANY $1.90
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 32.63
  • ANY 28.15
  • Support Level
  • BCAB $0.24
  • ANY $0.55
  • Resistance Level
  • BCAB $0.36
  • ANY $0.69
  • Average True Range (ATR)
  • BCAB 0.04
  • ANY 0.06
  • MACD
  • BCAB 0.01
  • ANY 0.00
  • Stochastic Oscillator
  • BCAB 29.39
  • ANY 11.82

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About ANY Sphere 3D Corp.

Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Digital Mining and Service and Product. The Digital Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.

Share on Social Networks: